Hedgehog Inhibition With the Orally Bioavailable Smo Antagonist LDE225 Represses Tumor Growth and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Neoplasms

@article{Fendrich2011HedgehogIW,
  title={Hedgehog Inhibition With the Orally Bioavailable Smo Antagonist LDE225 Represses Tumor Growth and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Neoplasms},
  author={Volker Fendrich and Dominik Wiese and Jens Waldmann and Matthias Lauth and Anna E. Heverhagen and Johannes Rehm and Detlef Klaus Bartsch},
  journal={Annals of Surgery},
  year={2011},
  volume={254},
  pages={818–823}
}
Background:This study was designed to evaluate the role of the hedgehog pathway in tumor progression of murine islet cell tumors. Blockade of aberrant hedgehog activation has recently been proposed as a therapeutic target, but effects in models of islet cell tumors with a new orally bioavailable Smoothened (Smo) antagonist LDE225 have not been examined. Material and Methods:To assess in vivo effects, transgenic Rip1Tag2 mice, which develop islet cell neoplasms, were treated with vehicle or… 
Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice
TLDR
A comparative analysis of the different treatment groups showed that combination therapy using sonidegib and 177Lu-octreotate could be beneficial to patients with neuroendocrine tumors.
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
TLDR
Hedgehog inhibition by NVP-LDE225 plus sunitinib or everolimus bolsters antitumour activity by interfering with tumour growth and metastatic spread, even in SuR cells.
Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma
TLDR
In vitro treatment of osteosarcoma cells with LDE225 resulted in a decreased ability of tumor cells to proliferate, but had no effect on their viability, suggesting that inhibiting Hh signaling can control osteosARcoma cell proliferation but does not modulate the immunogenic profile of these cells.
Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors.
TLDR
Enalapril and ASS may provide an approach for chemoprevention and treatment of pNENs and lead to significant downregulation of known target genes Vegf and Rela at RNA level.
Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model
TLDR
It is demonstrated for the first time that GLI inhibitor (Gant61), but not SMO inhibitor (LDE225), shows a potent inhibitory effect on LMS tumor growth and concomitantly suppresses the expression of GLI1- and GLI-targeted genes using the xenograft model of uterine LMS.
Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors
TLDR
Sorafenib may provide a new paradigm for the therapy of islet cell tumors because it significantly improved survival in the late treatment group and led to a dramatic decrease in tumor volume.
Efficacy and safety of sonic hedgehog pathway inhibitors in cancer
The hedgehog pathway, for which sonic hedgehog (Shh) is the most prominent ligand, is highly conserved and is tightly associated with embryonic development in a number of species. This pathway is
Anti-pancreatic cancer activity of Z-ajoene from garlic: An inhibitor of the Hedgehog/Gli/FoxM1 axis
Abstract Overexpression of glioma-associated oncogene (Gli), a transcription factor at the final step of Hedgehog (Hh) pathway, is involved in pancreatic cancer development. Therefore, inhibition of
Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer
TLDR
Three US FDA-approved drugs for cancers affect the Shh pathway, and one of these compounds is arsenic trioxide, which can suppress this pathway at the level of the GLI proteins, although current evidence suggests it also has other targets.
CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms.
TLDR
CUX1 mediates an invasive pro-angiogenic phenotype and is associated with malignant behaviour in human insulinomas, and endogenous and recombinant CUX1 expression increased tumour cell proliferation, tumour growth, resistance to apoptosis, and angiogenesis in vitro and in vivo.
...
1
2
3
4
...

References

SHOWING 1-10 OF 27 REFERENCES
Hedgehog Inhibition With Cyclopamine Represses Tumor Growth and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Tumors
TLDR
Hh inhibitors may provide a new paradigm for therapy of islet cell tumors in various stages, particularly their use in conjunction with conventional antimetabolites should be further evaluated.
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer
TLDR
A novel, orally bioavailable small-molecule Hedgehog inhibitor, IPI-269609, was tested using in vitro and in vivo model systems and profoundly inhibited systemic metastases in orthotopic xenografts established from human pancreatic cancer cell lines, although Hedgehog blockade had minimal effect on primary tumor volume.
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
TLDR
GDC-0449, an orally active small molecule that targets the hedgehog pathway, appears to have antitumor activity in locally advanced or metastatic basal-cell carcinoma.
Hedgehog-Gli signaling pathway inhibitors as anticancer agents.
TLDR
The medicinal chemistry efforts to identify and design inhibitors of Hh-Gli signaling are reviewed and a perspective of future developments in this dynamic field is presented.
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
TLDR
Studying a mouse model of PDA that is refractory to the clinically used drug gemcitabine, it is found that the tumors in this model were poorly perfused and poorly vascularized, properties that are shared with human PDA.
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
TLDR
It is reported that sonic hedgehog, a secreted hedgehog ligand, is abnormally expressed in pancreatic adenocarcinoma and its precursor lesions: pancreatic intraepithelial neoplasia (PanIN), and that maintenance of hedgehog signalling is important for aberrant proliferation and tumorigenesis.
Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade
TLDR
This compound caused regression of murine tumor allografts in vivo and induced rapid death of cells from freshly resected human medulloblastomas, but not from other brain tumors, thus establishing a specific role for Hh pathway activity in medullOBlastoma growth.
Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy
TLDR
This review covers the patent literature related to Hh pathway inhibitors for the treatment of proliferative diseases, regardless of their modes of action, and reports that most reported Hh pathways inhibitors act on the key signaling transducer Smoothened (SMO).
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours
TLDR
A wide range of digestive tract tumours, including most of those originating in the oesophagus, stomach, biliary tract and pancreas, but not in the colon, display increased Hh pathway activity, which is suppressible by cyclopamine, a Hh pathways antagonist.
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
TLDR
Anti-angiogenic drugs may prove most efficacious when they are targeted to specific stages of cancer, as seen in mice treated with RIP1-Tag2.
...
1
2
3
...